{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T02:46:27Z","timestamp":1760237187795,"version":"build-2065373602"},"reference-count":23,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,3,21]],"date-time":"2020-03-21T00:00:00Z","timestamp":1584748800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["AI118415","GM125396","T32-MH079785"],"award-info":[{"award-number":["AI118415","GM125396","T32-MH079785"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Fostemsavir\/temsavir is an investigational HIV-1 entry inhibitor currently in late-stage clinical trials. Although it holds promise to be a first-in-class Env-targeted entry inhibitor for the clinic, issues with bioavailability relegate its use to salvage therapies only. As such, the development of a small molecule HIV-1 entry inhibitor that can be used in standard combination antiretroviral therapy (cART) remains a longstanding goal for the field. We previously demonstrated the ability of extending the chemotypes available to this class of inhibitor as the first step towards this overarching goal. In addition to poor solubility, metabolic stability is a crucial determinant of bioavailability. Therefore, in this short communication, we assess the metabolic stabilities of five of our novel chemotype entry inhibitors. We found that changing the piperazine core region of temsavir alters the stability of the compound in human liver microsome assays. Moreover, we identified an entry inhibitor with more than twice the metabolic stability of temsavir and demonstrated that the orientation of the core replacement is critical for this increase. This work further demonstrates the feasibility of our long-term goal\u2014to design an entry inhibitor with improved drug-like qualities\u2014and warrants expanded studies to achieve this.<\/jats:p>","DOI":"10.3390\/molecules25061430","type":"journal-article","created":{"date-parts":[[2020,4,3]],"date-time":"2020-04-03T05:55:16Z","timestamp":1585893316000},"page":"1430","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Composition and Orientation of the Core Region of Novel HIV-1 Entry Inhibitors Influences Metabolic Stability"],"prefix":"10.3390","volume":"25","author":[{"given":"Rama","family":"Karadsheh","sequence":"first","affiliation":[{"name":"Department of Biochemistry &amp; Molecular Biology, Drexel University College of Medicine, Rooms 10307, 10309, and 10315, 245 North 15th Street, Philadelphia, PA 19102, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1544-606X","authenticated-orcid":false,"given":"Megan E.","family":"Meuser","sequence":"additional","affiliation":[{"name":"Department of Biochemistry &amp; Molecular Biology, Drexel University College of Medicine, Rooms 10307, 10309, and 10315, 245 North 15th Street, Philadelphia, PA 19102, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-741X","authenticated-orcid":false,"given":"Simon","family":"Cocklin","sequence":"additional","affiliation":[{"name":"Department of Biochemistry &amp; Molecular Biology, Drexel University College of Medicine, Rooms 10307, 10309, and 10315, 245 North 15th Street, Philadelphia, PA 19102, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,3,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1021\/jm034082o","article-title":"Discovery of 4-benzoyl-1-[(4-methoxy-1H-pyrrolo[2,3-b]pyridin-3-yl)oxoacetyl]-2-(R)-methylpiperazine (BMS-378806): A novel HIV-1 attachment inhibitor that interferes with CD4-gp120 interactions","volume":"46","author":"Wang","year":"2003","journal-title":"J. Med. Chem."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1093\/infdis\/jis432","article-title":"Pharmacodynamics, safety, and pharmacokinetics of BMS-663068, an oral HIV-1 attachment inhibitor in HIV-1-infected subjects","volume":"206","author":"Nettles","year":"2012","journal-title":"J. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"5439","DOI":"10.1016\/j.bmcl.2014.10.027","article-title":"Discovery and optimization of novel small-molecule HIV-1 entry inhibitors using field-based virtual screening and bioisosteric replacement","volume":"24","author":"Tuyishime","year":"2014","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.bmcl.2015.10.080","article-title":"Core chemotype diversification in the HIV-1 entry inhibitor class using field-based bioisosteric replacement","volume":"26","author":"Tuyishime","year":"2016","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Meuser, M.E., Rashad, A.A., Ozorowski, G., Dick, A., Ward, A.B., and Cocklin, S. (2019). Field-Based Affinity Optimization of a Novel Azabicyclohexane Scaffold HIV-1 Entry Inhibitor. Molecules, 24.","DOI":"10.3390\/molecules24081581"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1128\/JVI.03473-14","article-title":"A Native-Like SOSIP.664 Trimer Based on an HIV-1 Subtype B env Gene","volume":"89","author":"Pugach","year":"2015","journal-title":"J. Virol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1002\/cbdv.200900148","article-title":"Beyond Profiling: Using ADMET Models to Guide Decisions","volume":"6","author":"Segall","year":"2009","journal-title":"Chem. Biodivers."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.2174\/138161212799436430","article-title":"Multi-Parameter Optimization: Identifying High Quality Compounds with a Balance of Properties","volume":"18","author":"Segall","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10822-018-0107-0","article-title":"WhichP450: A multi-class categorical model to predict the major metabolising CYP450 isoform for a compound","volume":"32","author":"Hunt","year":"2018","journal-title":"J. Comput. Aided Mol. Des."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"S867","DOI":"10.1093\/ofid\/ofz360.2178","article-title":"Fostemsavir Drug\u2013Drug Interaction Profile, an Attachment Inhibitor and Oral Prodrug of Temsavir, for Heavily Treatment Experienced HIV-1-Infected Patients","volume":"6","author":"Moore","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1021\/acs.jcim.6b00233","article-title":"Predicting Regioselectivity and Lability of Cytochrome P450 Metabolism Using Quantum Mechanical Simulations","volume":"56","author":"Tyzack","year":"2016","journal-title":"J. Chem. Inf. Model."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1002\/cmdc.200700319","article-title":"Towards an integrated description of hydrogen bonding and dehydration: Decreasing false positives in virtual screening with the HYDE scoring function","volume":"3","author":"Reulecke","year":"2008","journal-title":"ChemMedChem"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"4210","DOI":"10.1021\/acs.jmedchem.5b01146","article-title":"Structure-Based Inhibitor Design for Evaluation of a CYP3A4 Pharmacophore Model","volume":"59","author":"Kaur","year":"2016","journal-title":"J. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1124\/dmd.106.010793","article-title":"Comparison of intrinsic clearance in liver microsomes and hepatocytes from rats and humans: Evaluation of free fraction and uptake in hepatocytes","volume":"34","author":"Lu","year":"2006","journal-title":"Drug Metab. Dispos."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7478","DOI":"10.1128\/jvi.71.10.7478-7487.1997","article-title":"Coreceptor usage of primary human immunodeficiency virus type 1 isolates varies according to biological phenotype","volume":"71","author":"Bjorndal","year":"1997","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/cmdc.201200577","article-title":"Identification of a small-molecule inhibitor of HIV-1 assembly that targets the phosphatidylinositol (4,5)-bisphosphate binding site of the HIV-1 matrix protein","volume":"8","author":"Zentner","year":"2013","journal-title":"ChemMedChem"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8472","DOI":"10.1128\/JVI.05006-11","article-title":"Inhibiting early-stage events in HIV-1 replication by small-molecule targeting of the HIV-1 capsid","volume":"86","author":"Kortagere","year":"2012","journal-title":"J. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pep.2005.01.016","article-title":"Protein production by auto-induction in high density shaking cultures","volume":"41","author":"Studier","year":"2005","journal-title":"Protein Expr. Purif."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1006\/viro.1995.1016","article-title":"Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes","volume":"206","author":"Connor","year":"1995","journal-title":"Virology"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"10020","DOI":"10.1128\/JVI.73.12.10020-10028.1999","article-title":"Species-specific, postentry barriers to primate immunodeficiency virus infection","volume":"73","author":"Hofmann","year":"1999","journal-title":"J. Virol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3645","DOI":"10.1128\/JVI.01778-06","article-title":"Broad-spectrum anti-human immunodeficiency virus (HIV) potential of a peptide HIV type 1 entry inhibitor","volume":"81","author":"Cocklin","year":"2007","journal-title":"J. Virol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6705","DOI":"10.1128\/jvi.69.11.6705-6711.1995","article-title":"Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity","volume":"69","author":"He","year":"1995","journal-title":"J. Virol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.ab.2006.08.005","article-title":"Exploring \u201cone-shot\u201d kinetics and small molecule analysis using the ProteOn XPR36 array biosensor","volume":"358","author":"Bravman","year":"2006","journal-title":"Anal. Biochem."}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/6\/1430\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:10:20Z","timestamp":1760173820000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/25\/6\/1430"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,21]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,3]]}},"alternative-id":["molecules25061430"],"URL":"https:\/\/doi.org\/10.3390\/molecules25061430","relation":{},"ISSN":["1420-3049"],"issn-type":[{"type":"electronic","value":"1420-3049"}],"subject":[],"published":{"date-parts":[[2020,3,21]]}}}